MPA approval in China of Sylvant for Idiopathic Multicentric Castleman Disease. BeiGene + EUSA Pharma
This disease is a rare, life-threatening, and debilitating condition of the lymph nodes and related tissues.
Siltuximab is a monoclonal antibody approved in the United States, European Union, and other countries and regions around the world.
The approval of siltuximab for the treatment of iMCD was supported by clinical results from a multinational, randomized, double blind, placebo-controlled Phase II trial (NCT01024036) conducted in 79 patients from 19 countries and regions, including 16 patients from China.
Related news and insights
GSK Australia is pleased to announce that the Therapeutic Goods Administration (TGA) has registered Zejula (niraparib) for the treatment of women with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer following completion of first-line platinum-based chemotherapy.
Bristol-Myers Squibb K.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have either experienced disease progression on the last therapy or relapse after the last therapy.